Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Dawson James Downgrades BioCardia to Neutral

Dawson James Downgrades BioCardia to Neutral

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

Stifel Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $5

By Benzinga Newsdesk

July 13, 7:28 AM

Stifel analyst Benjamin Burnett downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $16 to $5.

ATRA

JP Morgan Maintains Overweight on General Dynamics, Lowers Price Target to $245

By Benzinga Newsdesk

January 27, 9:46 AM

JP Morgan analyst Seth Seifman maintains General Dynamics (NYSE:GD) with a Overweight and lowers the price target from $260 to $245.

NLS Pharmaceutics’ Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors

By Vandana Singh

September 27, 12:02 PM

NLS Pharmaceutics Ltd (NASDAQ:NLSP) announced topline results from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), in…

NLSP

What’s Going On With ThredUp Shares Today?

By Sean Torres

March 7, 4:55 PM

ThredUp Inc. (NASDAQ: TDUP) shares are trading higher after the company reported better-than-expected Q4 sales and issued strong Q1 guidance.

TDUP

Dawson James Downgrades BioCardia to Neutral

Related Posts

Stifel Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $5

JP Morgan Maintains Overweight on General Dynamics, Lowers Price Target to $245

NLS Pharmaceutics’ Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors

What’s Going On With ThredUp Shares Today?